MedPath

Efficacy of pantoprazole suspension for prevention of peptic ulcer.

Phase 3
Conditions
peptic ulcer prevention.
Peptic ulcer, site unspecified
Registration Number
IRCT2015070220178N5
Lead Sponsor
Iran University of Medical Sciences,Rasoul Akram Hospital,Colorectal Research Center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
66
Inclusion Criteria

Patients older than 18 years who are admitted to medical and surgical ICUs with support of mechanical ventilation at least for 48 hours and nasogastric tube .
Exclusion criteria:active gastrointestinal bleeding,allergic history to pantoprazole ,co-administeration of prokinetic and other acid reducing drugs,past history of gastric surgery,nasogastric tube intolerance,liver failure,pregnancy, lactation,unexpected intragastric pH<0.8 and/or >10.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Peptic ulcer prevention. Timepoint: basic ,first day,third day. Method of measurement: 24 hours intragastric PH monitoring.
Secondary Outcome Measures
NameTimeMethod
Gastrointestinal bleeding rate after treatment intervention. Timepoint: 1,3 ,7,14 and 28 days after treatment intervention. Method of measurement: Data gathering sheet and nasogastric tube exam.;Drug adverse effect such as pneumonia rate. Timepoint: 3 ,7, 14 and 28 days after treatment intervention. Method of measurement: Sign and symptom gathering sheet and chest x-ray.;Frequency ofunderlying etiologic factore for mechanical ventilation support. Timepoint: at the begining of treatment. Method of measurement: Data gathering sheet.
© Copyright 2025. All Rights Reserved by MedPath